Other GLP-1 receptor agonists these should not be used at the same time as semaglutide
FDA guidelines state that they should only be prescribed to people with a BMI (body mass index) over 30kg/m, or a BMI over 27kg/mwith a weight-related medical condition
It binds to oxidative byproducts and supports their normal elimination through the liver
Complications such as cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), metabolic fatty liver disorder, obstructive sleep apnoea (OSA), osteoarthritis, anxiety, depression and some types of cancer are closely related to obesity and BMI increase [10, 20,21,22,23,24,25,26]
BMI is a number based on your height and weight
This comprehensive assessment gathers essential medical history, identifies absolute contraindications, and ensures patients understand both the benefits and risks of GLP-1 receptor agonist treatment